H. Lundbeck Company Description
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.
It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products.
The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals.
It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles.
H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies.
The company was founded in 1915 and is headquartered in Valby, Denmark.

Country | Denmark |
Founded | 1915 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 5,707 |
CEO | Charl van Zyl |
Contact Details
Address: Ottiliavej 9 Valby Denmark | |
Phone | 45 36 30 13 11 |
Stock Details
Ticker Symbol | HLUN.B |
Exchange | Copenhagen Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | DKK |
ISIN Number | DK0061804770 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Charl van Zyl | President and Chief Executive Officer |
Joerg Hornstein | Chief Financial Officer and Executive Vice President of Corporate Functions |
Lars Bang | Executive Vice President of Product Development and Supply |
Dr. Per Johan Luthman Ph.D. | Executive Vice President of Research and Development |
Dr. Tarek Samad Ph.D. | Senior Vice President and Head of Research |
Jens Hoyer | Vice President and Head of Investor Relations |
Tine Ostergaard Hansen | Senior Vice President of Corporate Communications and Public Affairs |
Dianne Holto | Executive Vice President of People and Culture |
Palle Holm Olesen | Chief Specialist and Vice President of Investor Relations |
Bjorn R. Mogensen | Senior Vice President of Group Finance |